Goodwill and Intangible Assets (Additional Information) (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended	9 Months Ended
	May 31, 2023	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Aug. 22, 2022	Feb. 17, 2022
Goodwill [Line Items]
Goodwill		$ 17,905,000			$ 17,905,000		$ 26,713,000
Amortization expense		6,511,000	$ 1,511,000		15,274,000	$ 1,511,000
Goodwill, impairment losses				$ 0
Collaboration agreement
Goodwill [Line Items]
Amortization expense		6,500,000	$ 1,500		15,300,000	$ 1,500
In-process research and development
Goodwill [Line Items]
Useful life of Remaining In Process Research and Development	$ 2,600,000
In-process research and development | Collaboration agreement
Goodwill [Line Items]
Amortization expense	$ 68,700,000			$ 0
La Jolla Pharmaceutical Company
Goodwill [Line Items]
Goodwill								$ 6,411,000
Future amortization expense, remainder of 2023		6,500			6,500
Future amortization expense, 2024		25,800,000			25,800,000
Future amortization expense, 2025		25,800,000			25,800,000
Future amortization expense, 2026		25,800,000			25,800,000
Future amortization expense, 2027		25,800,000			25,800,000
Future amortization expense, thereafter		124,500,000			124,500,000
Intangible assets pertain to product rights and developed technologies		151,000,000			151,000,000			$ 151,000,000
Entasis Therapeutics Holdings Inc
Goodwill [Line Items]
Goodwill									$ 11,493,000
Intangible assets pertain to product rights and developed technologies		106,700,000			106,700,000				$ 106,700,000
Entasis Therapeutics Holdings Inc | Collaboration agreement
Goodwill [Line Items]
Intangible assets pertain to product rights and developed technologies		35,400,000			35,400,000
Entasis Therapeutics Holdings Inc | In-process research and development
Goodwill [Line Items]
Intangible assets pertain to product rights and developed technologies		$ 71,300,000			$ 71,300,000